We are committed to our vision of turning hope into reality for patients with rare genetic skin diseases.
Dermelix is a clinical-stage biopharmaceutical company focused on delivering innovative treatments to patients suffering from rare genetic skin diseases. Our team consists of a small group of drug developers with extensive experience in getting drugs approved in the rare disease space. We are currently developing therapies across multiple innovative therapeutic modalities.
DMX-101 is a novel antenatal protein replacement therapy for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare pediatric genetic disease with no currently available corrective treatment options. We anticipate initiating a pivotal trial in XLHED patients in 2019.
DMX-102 utilizes an innovative genetic therapeutic approach called Spherical Nucleic Acid (SNA™) technology to topically deliver targeted oligonucleotide therapies directly to the site of action in the skin. Using this innovative approach, DMX-102 will target specific drivers of disease manifestation in a rare genetic pediatric skin condition called Netherton Syndrome (NS). We anticipate initiating a proof of concept clinical study in patients with NS by the end of 2020.